Endocyte Announces Presentation of Phase 2 Data from

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
70
Endocyte Announces Presentation of Phase 2 Data from Investigator-Initiated Prostate Cancer Trial of 177Lu-PSMA-617 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

  – PSA response rates in additional 20 mCRPC patients enrolled at Peter MacCallum Cancer Centre higher than previously reported for first group of 30 patients –

– Company to host and webcast investor event featuring physician panel on 177 Lu-PSMA-617 –

WEST LAFAYETTE, Ind., May 16, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq: ECYT ), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that a poster with data from the Peter MacCallum Cancer Centre will be presented on Endocyte’s lead investigational therapy at the 2018 ASCO Annual Meeting on Saturday, June 2, 2018. Updated data from the phase 2 study of 177 Lu-PSMA-617 as a potential treatment for metastatic castration-resistant prostate cancer (mCRPC), including data from an additional 20 patient expansion cohort, will be highlighted by the poster.

“We are very pleased that we continue to see high rates of PSA response, even in heavily pre-treated patients,” said Mike Sherman, president and CEO of Endocyte. “In the 50 patients receiving 177 Lu-PSMA-617, 62% had a greater than 50% reduction in their PSA levels. Further, 44% of patients had a PSA reduction of 80% or greater. We look forward to sharing more information on this phase 2 trial at ASCO. We recently reported median overall survival of 13.5 months for the first cohort of 30 patients enrolled. The median overall survival in the total 50 patients is not yet meaningful as follow-up in the second cohort of 20 patients is between 6 and 9 months at the time of cutoff. Updated survival metrics will be presented at a future medical conference as that data matures.”

ASCO Presentation Details: Abstract #:       5040 (Poster Board: #267) Title:                 Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial. When:              Saturday, June 2, 2018 at 1:15 p.m. – 4:45 p.m. CDT Session Title:   Genitourinary (Prostate) Cancer Location:          Hall A

Webcast Investor Event and 177 Lu-PSMA-617 Panel Discussion: The Company will host a reception and webcast panel discussing 177 Lu-PSMA-617 for investors and analysts on Monday, June 4, 2018 from 6:00 p.m.- 8:00 p.m. CDT. Panelists scheduled to participate at the event include:

  • Alison Armour, M.B., Ch.B., B.Sc, M.Sc, M.D., F.R.C.P., F.R.C.R., Chief Medical Officer, Endocyte
  • Johann S de Bono, M.D., M.Sc, Ph.D, F.R.C.P., Regius Professor of Cancer Research; Professor, The Royal Marsden NHS Foundation Trust (UK)
  • Oliver Sartor, M.D., C.E. & Bernadine Laborde Professor for Cancer Research; Medical Director, Tulane Cancer Center

A live audio webcast of the event can be accessed by visiting "Events & Presentations" under the Investors & News section of Endocyte's website at www.endocyte.com . The webcast will be archived shortly after the live event, and a replay will be available on the Company's website for at least 90 days following the event.

Website Information:

Endocyte routinely posts important information intended for investors on its website, www.endocyte.com , in the “Investors & News” section. Endocyte uses this website as a means of disclosing material information in legal compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the “Investors & News” section of Endocyte’s website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, the Endocyte website is not incorporated by reference into, and is not a part of, this document.

About Endocyte:

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead clinical program is an experimental prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, 177 Lu-PSMA-617, entering phase 3 for metastatic castration-resistant prostate cancer (mCRPC). Endocyte also expects to have an Investigational New Drug application submitted in the fourth quarter of 2018 for its adaptor-controlled CAR T-cell therapy which will be studied initially in osteosarcoma. For additional information, please regularly visit Endocyte's website at www.endocyte.com .

Forward Looking Statements:

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the company's future development plans and presentation and status of clinical data. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that the company or independent investigators may experience delays in submission and review of regulatory applications, execution of clinical trials and/or the processing of clinical data. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company’s periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 21

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 66

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
Corner Bakery Bets on Holiday Catering Convenience

Updated Category News Views 150

A $50 carrot on a $350 catering tab tells you exactly where Corner Bakery sees the holiday battlefield: not in one lonely cookie sale, but in the larger group order that can make a restaurant’s day. The chain is pushing holiday catering through November and December, pairing that discount with bakery trays, meals for groups and a promise to handle delivery setup. It is...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 7

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 135

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 95

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 38

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 180

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 65

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 110

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading

Top 5 Most Recently Viewed Articles

Pharvaris Shares Promising Data on Deucrictibant Efficacy

Updated Category News Views 186

Pharvaris Highlights Clinical Progress in HAE Treatment At the recent AAAAI/WAO Joint Congress, Pharvaris presented compelling long-term clinical data supporting the use of deucrictibant, a novel oral treatment for hereditary angioedema (HAE). This data underscores the drug's potential to not only prevent but also effectively address HAE attacks, offering hope to those...

Continue Reading
First Horizon Opens New Banking Center Celebrating Local Pride

Updated Category News Views 349

First Horizon Unveils New Banking Center with Appalachian Spirit First Horizon Bank (NYSE: FHN) proudly celebrated the grand opening of its newly refreshed banking center. The location pays tribute to the vibrant Appalachian State community, showcasing a striking theme that reflects its strong ties with Appalachian State University and its athletics. This celebration...

Continue Reading
Understanding Namodenoson's Role in Liver Cancer and Beyond

Updated Category News Views 243

Innovative Research on Namodenoson’s Impact in Liver Cancer Therapy Namodenoson, developed by Can-Fite BioPharma Ltd., is making waves in the medical community as a promising candidate for liver cancer treatment. Unlike traditional chemotherapy, which often harms healthy cells, Namodenoson is lauded for its protective qualities towards normal body systems. Published...

Continue Reading
Geotab Enhances Public Sector Solutions with Technological Advancements

Updated Category News Views 147

Geotab Enhances Public Sector Solutions with Technological Advancements Geotab Inc., a leader in connected vehicle solutions and asset management, has taken a major step forward in serving the public sector by expanding its cooperative purchasing contracts with Sourcewell and Canoe Procurement Group. This expansion introduces four cutting-edge solutions aimed at enhancing...

Continue Reading
Dun & Bradstreet Earns TRUSTe Certification for Responsible AI

Updated Category News Views 351

Dun & Bradstreet Achieves TRUSTe Responsible AI Certification Dun & Bradstreet (NYSE:DNB), recognized globally as a leading provider of business decisioning data and analytics, has been awarded the TRUSTe Responsible AI Certification. This certification signifies the company’s commitment to ethical and responsible governance in the realm of artificial intelligence (AI)....

Continue Reading